Lanreotide
Educational resource. Not medical advice. No dosing or instructions.
Safety grade
5/10
Moderate
Also known as
bim 23014bim-23014lanreotidesomatuline
AA sequence
Not available yet.
No overview has been added yet.
Why people are interested in this peptide and how it is commonly discussed in real-world wellness, rehabilitation, and athletic communities.
Why people are interested
- Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.
- general recovery and resilience interest (anecdotal)
- common biohacker curiosity due to community reports
- interest in mechanisms suggested by early evidence
- used in goal-based stacking discussions (anecdotal)
- exploration in wellness communities despite evidence limits
Lanreotide is a prescription somatostatin analog used for specific tumors and endocrine conditions. It is not a wellness peptide; non-medical use carries real endocrine and gallbladder risks.
Common reasons people consider it
- clinical use in acromegaly and certain neuroendocrine tumors (specialist care)
- reduces hormone secretion in specific medical contexts
- symptom control in supervised endocrine/oncology settings
Most commonly reported downsides
- diarrhea or loose stools
- abdominal pain
- nausea
- injection site reactions
- fatigue
Rare but important symptoms to watch for
These are uncommon, but if they occur, stop and seek medical care.
- gallbladder problems (severe right-upper abdominal pain, fever, jaundice)
- severe blood sugar disturbances (high or low blood sugar symptoms)
- slow heart rate symptoms (fainting, severe dizziness)
- severe allergic reaction symptoms (hives, facial swelling, trouble breathing)
Who should be cautious
- anyone without specialist supervision for a defined indication
- people with diabetes or unstable blood sugar control
- people with gallbladder disease history
- pregnant or breastfeeding individuals
- adolescents (high-consequence endocrine manipulation plus inappropriate use context)
Interactions summarize known or plausible ways this peptide may intersect with medications, supplements, or physiologic states. Use this as a risk-awareness map: what to ask about, what to watch for, and what deserves a clinician conversation.
No interaction details have been added yet.
Developmental risk is flagged due to limited adolescent data and uncertain long-term effects. Endocrine, growth, neurodevelopmental, and metabolic setpoints may be sensitive to perturbation. This section is descriptive only; uncertainty is explicitly acknowledged.
No curated human clinical sources have been added yet.
Pep-Talk curation pending: we’re reviewing the evidence and will expand this section soon.
Pep-Talk is informational only and not medical advice. We make no warranties and are not liable for actions you take. You are responsible for your decisions and outcomes.
Community notes
Educational discussion only. No dosing, protocols, schedules, or instructions. Submissions are moderated before appearing.
Loading…
Submit a note